Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-16T22:25:45.177Z Has data issue: false hasContentIssue false
  • English
  • Français

The coronavirus disease 2019 (COVID-19) pandemic—Looking back and looking forward

Published online by Cambridge University Press:  02 August 2021

David K. Henderson ,
Sarah Haessler  and
David J. Weber
David K. Henderson*
Affiliation:
Clinical Center, National Institutes of Health, Bethesda, Maryland
Sarah Haessler
Affiliation:
Baystate Health, Bethesda, Maryland
David J. Weber
Affiliation:
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
*
Author for correspondence: David K. Henderson, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Commentary
Information
Infection Control & Hospital Epidemiology , Volume 42 , Issue 10 , October 2021 , pp. 1245 - 1250
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Weber, DJ, Babcock, H, Hayden, MK, et al. Universal pandemic precautions—an idea ripe for the times. Infect Control Hosp Epidemiol 2020;41:1321–1322.CrossRefGoogle ScholarPubMed
World Health Organization. Coronavirus disease (COVID-19) pandemic: about the virus. World Health Organization website. ˜https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/novel-coronavirus-2019-ncov#:˜:text=A%20novel%20coronavirus%20was%20identified,cold%20to%20more%20severe%20diseases. Published 2021. Accessed June 30, 2021.Google Scholar
Wu, F, Zhao, S, Yu, B, Chen, YM, Wang, W, Song, ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265–269.CrossRefGoogle ScholarPubMed
Beigel, JH, Tomashek, KM, Dodd, LE, et al. Remdesivir for the treatment of COVID-19— final report. N Engl J Med 2020;383:1813–1826.CrossRefGoogle ScholarPubMed
Gillenwater, S, Rahaghi, F, Hadeh, A. Remdesivir for the treatment of COVID-19— preliminary report. N Engl J Med 2020;383:992.Google ScholarPubMed
An EUA for casirivimab and imdevimab for COVID-19. Med Lett Drugs Ther 2020;62:201–202.Google Scholar
Dhand, A, Lobo, SA, Wolfe, K, et al. Casirivimab-imdevimab for treatment of COVID-19 in solid organ transplant recipients: an early experience. Transplantation 2021;105:e68–e69.CrossRefGoogle Scholar
Group A-TL-CS, Lundgren, JD, Grund, B, et al. A neutralizing monoclonal antibody for hospitalized patients with COVID-19. N Engl J Med 2021;384:905–914.Google ScholarPubMed
Simonovich, VA, Burgos Pratx, LD, Scibona, P, et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med 2021;384:619–629.CrossRefGoogle ScholarPubMed
Lescure, FX, Honda, H, Fowler, RA, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2021;9:522–532.Google ScholarPubMed
Praveen, D, Puvvada, RC, M VA. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. Int J Antimicrob Agents 2020;55:105967.Google Scholar
Rosas, IO, Brau, N, Waters, M, et al. Tocilizumab in hospitalized patients with severe COVID-19 pneumonia. N Engl J Med 2021;384:1503–1516.CrossRefGoogle ScholarPubMed
Landscape of COVID-19 candidate vaccines. World Health Organization website. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Updated May 11, 2021. Accessed June 30, 2021.Google Scholar
FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine. US Food and Drug Administration website. https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19. Published December 11, 2020. Accessed June 30, 2021.Google Scholar
FDA takes additional action in fight against COVID-19 by issuing emergency use authorization for second COVID-19 vaccine. US Food and Drug Administration website. https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid. Published December 18, 2020. Accessed June 30, 2021.Google Scholar
FDA issues emergency use authorization for third COVID-19. US Food and Drug Administration website. ˜https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine#:˜:text=Today%2C%20the%20U.S.%20Food%20and,SARS%2DCoV%2D2. Published February 27, 2021. Accessed June 30, 2021.Google Scholar
Baden, LR, El Sahly, HM, Essink, B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403–416.CrossRefGoogle ScholarPubMed
Polack, FP, Thomas, SJ, Kitchin, N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603–2615.CrossRefGoogle ScholarPubMed
Sadoff, J, Gray, G, Vandebosch, A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med 2021;384:2187–2201.CrossRefGoogle ScholarPubMed
DeSalvo, K, Hughes, B, Bassett, M, et al. Public health COVID-19 impact assessment: lessons learned and compelling needs. NAM Perspect 2021. doi.org/10.31478/202104c.CrossRefGoogle ScholarPubMed
Lee, N, Hui, D, Wu, A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986–1994.Google Scholar
Zaki, AM, van Boheemen, S, Bestebroer, TM, Osterhaus, AD, Fouchier, RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814–1820.CrossRefGoogle ScholarPubMed
Arons, MM, Hatfield, KM, Reddy, SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med 2020;382:2081–2090.CrossRefGoogle Scholar
Gandhi, M, Yokoe, DS, Havlir, DV. Asymptomatic transmission, the Achilles’ heel of current strategies to control COVID-19. N Engl J Med 2020;382:2158–2160.Google ScholarPubMed
McMichael, TM, Clark, S, Pogosjans, S, et al. COVID-19 in a long-term care facility—King County, Washington, February 27–March 9, 2020. Morb Mortal Wkly Rep 2020;69:339–342.CrossRefGoogle Scholar
Stokes, EK, Zambrano, LD, Anderson, KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020. Morb Mortal Wkly Rep 2020;69:759–765.CrossRefGoogle ScholarPubMed
Killerby, ME, Link-Gelles, R, Haight, SC, et al. Characteristics associated with hospitalization among patients with COVID-19—metropolitan Atlanta, Georgia, March–April 2020. Morb Mortal Wkly Rep 2020;69:790–794.CrossRefGoogle ScholarPubMed
Mathieu, E, Ritchie, H, Ortiz-Ospina, E, et al. A global database of COVID-19 vaccinations. Nat Hum Behav 2021. doi: 10.1038/s41562-021-01122-8.Google ScholarPubMed
Kemp, SA, Collier, DA, Datir, RP, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature 2021;592:277–282.CrossRefGoogle ScholarPubMed
Nath, A. Long-Haul COVID. Neurology 2020;95:559–560.Google ScholarPubMed
Evaluating and caring for patients with post-COVID conditions: interim guidance. Centers for Disease Control and Prevention website. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-index.html. Updated June 14, 2021. Accessed June 30, 2021.Google Scholar
Turner, JS, Kim, W, Kalaidina, E, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature 2021;595:421–425.CrossRefGoogle ScholarPubMed
Wang, Z, Muecksch, F, Schaefer-Babajew, D, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021;595:426–431.CrossRefGoogle ScholarPubMed
Chodick, G, Tene, L, Patalon, T, et al. The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13—24 days after immunization: real-world evidence. medRxiv 2021.doi: 10.1101/2021.01.27.21250612v1.Google Scholar
Deepak, P, Kim, W, Paley, MA, et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv 2021. doi: 10.1101/2021.04.05.21254656.Google Scholar
Rabinowich, L, Grupper, A, Baruch, R, et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol 2021;75:435–438.CrossRefGoogle ScholarPubMed
Rozen-Zvi, B, Yahav, D, Agur, T, et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect 2021. doi: 10.1016/j.cmi.2021.04.028.CrossRefGoogle ScholarPubMed
Yelin, I, Katz, R, Herzel, E, et al. Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities. medRxiv 2021. doi: 10.1101/2021.03.16.21253686v2.Google Scholar
Greinacher, A, Thiele, T, Warkentin, TE, Weisser, K, Kyrle, PA, Eichinger, S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021;384:2092–2101.CrossRefGoogle ScholarPubMed
Schultz, NH, Sorvoll, IH, Michelsen, AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021;384:2124–2130.CrossRefGoogle ScholarPubMed
Scully, M, Singh, D, Lown, R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021;384:2202–2211.CrossRefGoogle ScholarPubMed
Myocarditis and pericarditis following mRNA COVID-19 vaccination Centers for Disease Control and Prevention website. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html. Updated June 23, 2021. Accessed June 30, 2021.Google Scholar
Shay, DK, Shimabukuro, TT, DeStefano, F. Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines. JAMA Cardiol 2021. doi: 10.1001/jamacardio.2021.2821.CrossRefGoogle ScholarPubMed
Leung, NHL, Chu, DKW, Shiu, EYC, et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med 2020;26:676–680.CrossRefGoogle ScholarPubMed
Weber, DJ, Al-Tawfiq, J, Hilary Babcock, H, et al. SHEA Statement: COVID-19 vaccination as a condition of employment for healthcare personnel. Infect Control Hosp Epidemiol 2021. In press.CrossRefGoogle ScholarPubMed